Sangamo Therapeutics (SGMOQ) Accumulated Expenses (2010 - 2025)

Sangamo Therapeutics has reported Accumulated Expenses for 16 years, with the latest figure at $17.7 million in Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 21.63% year-over-year to $17.7 million in Q4 2025; TTM through Dec 2025 was $17.7 million, a 21.63% increase from a year earlier, with the FY2025 full-year figure at $17.7 million, up 21.63% from the prior year.
• Accumulated Expenses was $17.7 million for Q4 2025 at Sangamo Therapeutics, up from $17.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $23.6 million in Q4 2023, with the low at $11.6 million in Q3 2024.
• Average Accumulated Expenses over 5 years is $17.0 million, with a median of $17.2 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Accumulated Expenses surged 60.15% in 2021, then tumbled 38.15% in 2024.
• Over 5 years, Accumulated Expenses stood at $20.8 million in 2021, then gained by 3.2% to $21.5 million in 2022, then climbed by 9.52% to $23.6 million in 2023, then sank by 38.15% to $14.6 million in 2024, then increased by 21.63% to $17.7 million in 2025.
• The last three Accumulated Expenses figures came in at $17.7 million (Q4 2025), $17.1 million (Q3 2025), and $15.4 million (Q2 2025), per Business Quant data.